RARE DISEASES ENVIRONMENT
ITALIAN ENVIRONMENT FOR RARE DISEASES
that as many as 5000 to 7000 distinct rare diseases exist, affecting for most of them a very small number of patients.
A DISEASE OR DISORDER
is defined as rare in Europe when it affects fewer than 1 in 2000 people.
for most of these diseases, for most of these patients and their families, are still to be invented, registered and marketed.
– life-threatening or chronically debilitating diseases which are of such low prevalence that special combined efforts are needed to address them –
RARE INSIGHT CONSULTING HAS BEEN CREATED TO SUPPORT HEALTHCARE COMPANIES
– will help new start-up biopharmaceutical companies establish their presence in Italy & Europe, as well as assisting well-established companies to bring solutions to people suffering from severe or orphan diseases. –
OUR VISION, OUR MISSION
To be the point of reference for healthcare companies that intend to operate in the Italian orphan drugs market, thus helping to improve the quality of life of rare disease patients.
We offer strategic support and operational solutions that are personalized, flexible and value-generating to healthcare companies offering effective therapies to people suffering from rare and severe diseases.
We help start-ups as well as established companies:
- To assess the potential of new business opportunities
- To establish, develop and strengthen their presence in Italy as well as rest of Europe
- To help them enhance their services at all stages of the products’ lifecycle
We believe that it is essential to know the history of our customers, and understand how they create value so as to be able to support them. We believe that active listening and open communication is essential. We do not make promises that we cannot keep, and we do not create false expectations. We are aware that the ultimate goal of our work is to improve the lives of patients suffering from rare diseases.
We keep abreast of the latest research and innovations that will change the world of medicine in the coming years.
We believe it is important to understand in which direction our society will progress and contribute to its sustainable improvement.
We believe that rigorous application of scientific methods is essential for interpreting data which helps communicating facts about diseases and their management.
ETHICS AND TRANSPARENCY
The achievement of objectives can never take precedence over compliance with the highest ethical standards and we shy away from the idea of easy shortcuts.
COMMITMENT & PASSION
The results we generate are the consequence of the passion that we put into what we do.
Talent is useful but must be nourished with constant commitment.
SENSE OF RESPONSIBILITY
The determination with which we pursue the achievement of results is always combined with a broader evaluation of consequences of our actions.
PERSONAL AND PROFESSIONAL GROWTH
Professional life is a journey in which experience and skills are accumulated over time.
Our ambition is to grow constantly as people and as professionals.
(RESPECT AND LOYALTY)
Open and transparent communication is essential.
We want to create an environment in which everyone can express their ideas, even if they disagree with the group, without altering the climate of mutual respect and loyalty.
Working as a united team gives us an opportunity to learn from each other and excel in what we do.
IS SUPPORTED BY:
Orphan/Biotech Drugs market
of the commercial process in the
in pharma companies start-up
WITH MORE THAN 30 YEARS IN THE PHARMACEUTICAL INDUSTRY, LEONARDO BRINGS AN EXTENSIVE KNOWLEDGE OF THE COMMERCIAL PROCESS AND A SOLID EXPERIENCE IN PHARMA COMPANIES START-UP AND MANAGEMENT.
Leonardo is founder of BluPhytal, a company which, through its Rare Insight Consulting division, supports healthcare companies to develop their presence in the Orphan Disease arena.
From 2016 to 2019 Leonardo has served as Head of Global Rare Diseases Franchise at Chiesi, managing the Strategic Marketing process and supporting Business Development activities.
From 2008 to 2015 Leonardo has created and developed the Italian affiliate of Swedish Orphan Biovitrum (SOBI), managing also Greece and Malta territories. In this role Leonardo has represented SOBI into Assobiotec (Italian Association for the Development of Biotechnologies) becoming member of the directive board.
Previously has spent 20 years in Chiesi Farmaceutici in positions with increasing responsibility in operational and strategic marketing, mainly in rare or severe diseases
RARE INSIGHT CONSULTING CAN PROVIDE, DIRECTLY OR THROUGH A NETWORK OF SELECTED PARTNERS, A WIDE RANGE OF SERVICES FROM STRATEGIC ADVICE TO PRACTICAL SOLUTIONS.
FIELDS OF EXPERTISE
ORGANIZATIONAL SET UP AND GROWTH PLANNING
MARKETING AND COMMUNICATION
COMMERCIAL OPERATIONS, DISTRIBUTION AND TENDER
MARKET ACCESS AND REGULATORY SUPPORT
MARKET RESEARCH AND ASSESSMENT
GO ON, CONTACT US!
INTERNATIONAL STRATEGIC PARTNERSHIP
RareInsight consulting is one of the 5 members of BlueDil International.
Together with our partners, based in Göttingen, London, Madrid, Paris, we offer to our customers an unique entry point to access the European markets.
At each stage of your product life cycle, BlueDil int’l conducts a wide range of strategic and operational missions in Europe, establishing strong relationship with local stakeholders (scientific community, KOLS) from patient associations to health authorities to simplify local market access process.
BlueDil International strength?
We understand that each situation is unique, and we provide customized, cost-effective, low-risk, totally compliant solutions working for you all over Europe.
WE HAVE WORKED WITH THESE COMPANIES
SUCCESSFUL SOLUTIONS FOR YOU!
TAKE A LOOK AT CASE STUDIES OF OUR CHOSEN COMPANY
Rare Insight has been and is an extremely valuable partner for Laboratoires CTRS.
They have effectively supported us in all phases (early access, price & reimbursement, launch strategy and tactics in the Italian market, KOL mapping, effective presentation of Orphacol advantages to treating physicians) allowing Orphacol to reach 100% of eligible patients.
Marco Liguori – Head of International Commercial Operations
There were some markets that were more difficult, in terms of previous relations we had with the Key Opinion Leaders, I have in mind for instance UK and ITALY and for some of these countries we have been able really to repair the relationships because of the local presence that was built.
Xavier Paoli – Pharnext Chief Commercial Officer
We are proud to see that our local presence, combined with strong experience and flexibility has been appreciated and made possible the development of the project in Italy, in coordination with our strategic partner BlueDil International.
Watch our partner testimony In the video below.